Madrigal Pharmaceuticals shares were higher in Thursday trading as attention returned to the company’s Rezdiffra launch trajectory and 2026 growth commentary following its most recent quarterly results and corporate update. In that update, Madrigal reported fourth-quarter 2025 Rezdiffra net sales of $321.1 million and full-year 2025 net sales of $958.4 million, alongside expectations for another year of robust net sales growth in 2026.

Rezdiffra is the company’s core value driver, and the market continues to price the stock primarily on whether the drug can sustain strong demand while maintaining broad access with payers. The latest company messaging emphasized broad first-line access and expanding disease awareness as drivers for continued growth, which helps reinforce the narrative that the initial commercial ramp is durable rather than a one-time launch spike.

Trading moves can be magnified by positioning in a high-volatility biotech name, especially when sentiment turns constructive. Recent market data sources show short interest at roughly 4.0 million shares (about 18.8% of float), a level that can contribute to sharper intraday moves if buyers step in and short-covering accelerates.

Investors are likely to keep the spotlight on any fresh payer-access disclosures, prescriptions/patient-on-therapy trends, and updates on pipeline programs intended to expand the long-term MASH franchise. With the most recent financial update still relatively fresh, the next incremental catalysts are typically investor presentations, potential analyst note flow, and the next earnings report window.